This funding will support the development and commercialization of our supervised AI-driven platform aimed at enhancing Deep Brain Stimulation (DBS) procedures for Parkinson’s Disease. The investment will help us expand globally, particularly in Europe and the US, and continue our innovations in neurosurgery.
Read the full article in French here.
An English translation by Google is available here.
Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...
An innovative and automated method RebrAIn’s service is based on a machine learning model trained on data from successfully treated patients. Using only a standard 3D T1 MRI, the algorithm automatically computes the stereotactic coordinates of the optimal DBS target,...
Already FDA 510(k) cleared in 2024, OptimMRI is an AI-powered surgical planning platform that supports Deep Brain Stimulation (DBS) and lesioning procedures (HIFU & Radiosurgery) targeting the STN and VIM regions. With MDR certification now secured, RebrAIn is...